EPIVAX, INC.
1 known investors
Find your way into EPIVAX, INC.
EpiVax works with biologic and vaccine developers to assess and manage immunogenicity risk across the product lifecycle, combining in silico analysis with in vitro testing to produce actionable immunogenicity data. The company helps pharmaceutical and vaccine partners reduce risk and build regulatory-ready strategies for safer therapies.
Founders & leadership
Investors · 1
Non-dilutive funding · 16 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2023 | $299.9K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2018 | $325K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2017 | $316.9K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2016 | $590.5K |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2012 | $1.5M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2012 | $757.7K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2012 | $600K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2008 | $600K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2007 | $299.9K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2007 | $263.9K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2005 | $1M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2005 | $609.9K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2004 | $831.9K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2001 | $247.8K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2001 | $105.6K |
| Department of Health and Human Services | Phase I | 1999 | $100K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
Frequently asked questions
- What does EPIVAX, INC. do?
- EpiVax works with biologic and vaccine developers to assess and manage immunogenicity risk across the product lifecycle, combining in silico analysis with in vitro testing to produce actionable immunogenicity data. The company helps pharmaceutical and vaccine partners reduce risk and build regulatory-ready strategies for safer therapies.
- Who founded EPIVAX, INC.?
- EPIVAX, INC. was founded by Annie De Groot MD.
- Who are EPIVAX, INC.'s investors?
- EPIVAX, INC.'s investors include SV Health Investors.